Twenty-two newbie managers, fresh from B-schools across India, are raring to go. Only, they won’t make spreadsheets to sell soaps or fizzy drinks. From June, they will assist senior bureaucrats across 11 districts of Jharkhand where the Centre is funding uplift schemes. These managers — from IIT-Kharagpur, Tata Institute of Social Sciences (TISS)-Mumbai, Visva-Bharti in Bengal’s Santiniketan, XISS-Ranchi, XLRI-Jamshedpur and others — are Prime Minister’s Rural Development Fellows in some of...

There is a complicated relationship between abortion as such and the selective abortion of female foetuses. This dilemma is one with which the women’s movement in India has been grappling since the late 1980s. In my discussion of this dilemma, I would like to move away completely from Satyamev Jayate, the television programme, (on which a discussion has been initiated by Shohini Ghosh on kafila.org). In any case, there the...

-The Telegraph The decade-long flow of funds from the Bill and Melinda Gates Foundation into India’s HIV control efforts will stop from June 2013, a foundation official said today, intensifying fears among sections of health activists about the future of the programme. Avahan was the first large-scale health initiative in India to be supported by the foundation, said to be t he world’s largest philanthropic organisation, and will be the first to...

Doctors across India who encounter patients with tuberculosis will have to disclose the identity, age, sex, and address of each patient to local health authorities under an order issued this week by the Union health ministry. The health ministry said today that it is essential to have complete information as part of its efforts to ensure that patients receive proper diagnosis and therapy and to curb the emergence and spread of...

-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...